Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30^th through February 1^st.

ORLANDO, FL / ACCESSWIRE / January 29, 2024 / Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Dealflow Events MicroCap Conference taking place January 30^th through February 1 in Caesars Atlantic City. Company CEO, Gareth Sheridan will make two presentations and answer questions at their conclusion.

Information about the Conference can be found here along with instructions how to request a one on one meeting with the company - https://themicrocapconference.com

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA abuse deterrence technology. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words 'believes,' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2023 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:

Patrick Ryan
CTO Nutriband Inc
[e-mail] / [e-mail]
121 S Orange Ave, Orlando, FL, 32407
[phone]

SOURCE: Nutriband Inc.

View the original press release on accesswire.com